Brief: Carmat Gets FDA Conditional Approval To Start Second EFS Study Cohort In The US
14/04/2025 17:21
April 14 (Reuters) - Carmat SA ALCAR.PA: RECRUITMENT FOR SECOND COHORT EXPECTED TO BEGIN IN H2 2025 CARMAT: RECRUITMENT OF SECOND COHORT EXPECTED TO BEGIN IN H2 2025 CARMAT RECEIVES FDA CONDITIONAL APPROVAL TO INITIATE THE SECOND COHORT OF THE EFS STUDY IN THE UNITED STATES TO INITIATE IMPLANTS IN SECOND HALF OF 2025 EFS STUDY INVOLVES 10 PATIENTS, PRIMARY ENDPOINT IS 6-MONTH SURVIVAL TO SEEK FDA APPROVAL FOR LATEST VERSION OF AESON Source text: ID:nBw1P1xYRa Further company coverage: ALCAR.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Carmat SA
See all newsBrief: Carmat Receives Takeover Bid
Brief: Carmat SAS Submits Bid For Carmat SA Within Ongoing Receivership Procedure
Brief: Carmat Says Liquidation Review Postponed Until Nov 25
Brief: Carmat: Judiciary Administrator Has Submitted Request To Convert Receivership Into Liquidation To Court
Carmat says imminent liquidation now 'extremely probable'